Corbus Pharmaceuticals (CRBP) Competitors $9.17 +0.20 (+2.23%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP vs. SEPN, PGEN, PRTC, CMPS, ORGO, SIGA, SAGE, ETON, BNTC, and MREOShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Septerna (SEPN), Precigen (PGEN), PureTech Health (PRTC), COMPASS Pathways (CMPS), Organogenesis (ORGO), SIGA Technologies (SIGA), Sage Therapeutics (SAGE), Eton Pharmaceuticals (ETON), Benitec Biopharma (BNTC), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Its Competitors Septerna Precigen PureTech Health COMPASS Pathways Organogenesis SIGA Technologies Sage Therapeutics Eton Pharmaceuticals Benitec Biopharma Mereo BioPharma Group Septerna (NASDAQ:SEPN) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the MarketBeat Community favor SEPN or CRBP? Corbus Pharmaceuticals received 453 more outperform votes than Septerna when rated by MarketBeat users. Likewise, 67.20% of users gave Corbus Pharmaceuticals an outperform vote while only 66.67% of users gave Septerna an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes666.67% Underperform Votes333.33% Corbus PharmaceuticalsOutperform Votes45967.20% Underperform Votes22432.80% Is SEPN or CRBP more profitable? Septerna's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Corbus Pharmaceuticals N/A -42.28%-32.92% Does the media refer more to SEPN or CRBP? In the previous week, Septerna had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Septerna and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.83 beat Septerna's score of 1.61 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corbus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer SEPN or CRBP? Septerna presently has a consensus target price of $27.00, indicating a potential upside of 159.37%. Corbus Pharmaceuticals has a consensus target price of $50.88, indicating a potential upside of 454.80%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has better earnings and valuation, SEPN or CRBP? Septerna has higher revenue and earnings than Corbus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$977K474.77N/AN/AN/ACorbus PharmaceuticalsN/AN/A-$44.60M-$4.22-2.17 Do insiders & institutionals believe in SEPN or CRBP? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCorbus Pharmaceuticals beats Septerna on 8 of the 13 factors compared between the two stocks. Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.21M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.968.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book-5.886.597.064.69Net Income-$44.60M$143.75M$3.23B$248.14M7 Day Performance4.20%3.72%2.67%2.39%1 Month Performance28.07%11.01%8.82%6.05%1 Year Performance-82.11%3.87%31.44%13.60% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.1371 of 5 stars$9.17+2.2%$50.88+454.8%-82.2%$112.21MN/A-1.9640Positive NewsSEPNSepterna2.2147 of 5 stars$10.11-1.0%$27.00+167.1%N/A$450.48M$977K0.00N/APositive NewsAnalyst RevisionPGENPrecigen4.1513 of 5 stars$1.50flat$5.50+266.7%-8.5%$442.77M$4.20M-2.73190News CoveragePositive NewsAnalyst ForecastAnalyst RevisionPRTCPureTech Health2.2467 of 5 stars$18.31-3.6%$45.00+145.8%-35.4%$439.79M$4.32M0.00100Positive NewsCMPSCOMPASS Pathways2.6352 of 5 stars$4.67-2.7%$18.83+303.3%-28.2%$436.94MN/A-2.12120Positive NewsGap UpHigh Trading VolumeORGOOrganogenesis4.6328 of 5 stars$3.44+13.5%$5.50+59.9%+20.4%$436.38M$458.76M-57.33950Positive NewsAnalyst RevisionSIGASIGA Technologies2.8408 of 5 stars$6.06+0.5%N/A-19.3%$432.93M$120.33M5.0540News CoveragePositive NewsOptions VolumeSAGESage Therapeutics3.5955 of 5 stars$6.81-0.6%$8.87+30.2%-36.1%$426.45M$47.40M-1.03690ETONEton Pharmaceuticals2.5183 of 5 stars$15.85-5.9%$29.67+87.2%+316.9%$425.07M$48.33M-72.0520Positive NewsShort Interest ↑Analyst RevisionHigh Trading VolumeBNTCBenitec Biopharma2.261 of 5 stars$16.17+1.1%$24.71+52.8%+120.8%$424.46M$80K-10.7120MREOMereo BioPharma Group1.9278 of 5 stars$2.65-3.3%$7.71+191.1%-24.7%$421.35M$1M-37.8640Analyst Revision Related Companies and Tools Related Companies SEPN Alternatives PGEN Alternatives PRTC Alternatives CMPS Alternatives ORGO Alternatives SIGA Alternatives SAGE Alternatives ETON Alternatives BNTC Alternatives MREO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
